A North American population’s predictors of early clopidogrel discontinuation after drug-eluting stent implantation




Background


The association between early discontinuation of clopidogrel after drug-eluting stent (DES) implantation and an increase risk of adverse cardiovascular events is well documented. However, little is known about the prevalence and predictors of premature discontinuation at this time; therefore, we sought to evaluate them in our population.




Methods


Patients who underwent DES implantation and were discharged on dual-antiplatelet therapy (DAPT) were divided into two groups: whether they discontinued prematurely the clopidogrel or not. We collected their demographic and baseline data and compared them.




Methods


Patients who underwent DES implantation and were discharged on dual-antiplatelet therapy (DAPT) were divided into two groups: whether they discontinued prematurely the clopidogrel or not. We collected their demographic and baseline data and compared them.

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Coronary stenting with MGuard: extended follow-up of first human trial
  2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
  3. Statin improves outcome of patients presenting with first acute myocardial infarction
  4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on A North American population’s predictors of early clopidogrel discontinuation after drug-eluting stent implantation

Full access? Get Clinical Tree
Get Clinical Tree app for offline access